1. Introduction {#sec1}
===============

Nonsynonymous single nucleotide polymorphisms (nsSNPs) are single base changes in coding regions that cause an amino acid substitution in the correspondent proteins. These missense variants constitute the most identifiable group of SNPs represented by a small (\<1%) proportion \[[@B1]\]. The nsSNPs might alter structure, stability, and function of proteins and produce the least conservative substitutions with drastic phenotypic consequences \[[@B2]--[@B5]\]. Studies suggest that about 60% of Mendelian diseases are caused by amino acid exchanges \[[@B6]\]. Thousands of associations between Mendelian and complex diseases reveal a phenotypic code that links each complex disorder to a unique set of Mendelian loci \[[@B7]\]. Discriminating disease-associated from neutral variants would help to understand the genotype/phenotype relation and to develop diagnosis and treatment strategies for diseases. Nonetheless, the most important application is the evaluation of functional effect and impact of genomic variation, relating interactions with phenotypes translating the finding into medical practices.

ATP-binding cassette transporter ABCA1 gene also known as the cholesterol efflux regulatory protein (CERP) encodes a 220 kDa protein \[[@B8]\]. This protein is crucial for reverse cholesterol transport and is considered as an important target in antiatherosclerosis treatment. ABCA1 mediates the efflux of cholesterol and phospholipids to lipid-poor apolipoproteins (apoA1 and apoE), which form nascent high-density lipoproteins (HDL). ABCA1 resides on the cell membrane and has an extensive intracellular pathway, with rapid movement of the transporter between the cell membrane and intracellular vesicles \[[@B9]\]. ABCA1 is present in higher quantities in tissues that transfer or are involved in the turnover of lipids such as the liver, the small intestine, and adipose tissue \[[@B10]--[@B12]\]. As well, lipid export activity of ABCA1 improves the function of pancreatic cells and ameliorates insulin release \[[@B13]\], reduces biliary cholesterol content protecting against gallstone \[[@B14]\], and plays a key role in lipid homeostasis in the lung \[[@B15]\]. Besides, evidence suggest a causal link between ABCA1 as cholesterol transporter and its antitumor activity \[[@B16], [@B17]\], as well as its implication in brain cholesterol homeostasis \[[@B15]--[@B20]\] founding lipid and myelin abnormalities in schizophrenia and Alzheimer\'s disease \[[@B18]--[@B20]\].

Although the entire ABCA1 protein 3D-structure remains unknown electron microscopic studies suggest a structural model consisting of a transmembrane domain (TMD) and a nucleotide-binding domain (NBD) ([Figure 1](#fig1){ref-type="fig"}) \[[@B14], [@B21], [@B22]\], where an NBD-TMD dimer is the minimum unit required for transport function \[[@B22], [@B23]\]. Also, X-ray structures are available for different domains in the C-terminus protein essential for lipid efflux activity \[[@B24], [@B25]\]. Many variants disrupting the normal ABCA1 protein function result in modest or no circulating HDL \[[@B26]--[@B32]\]. Cholesterol accumulated within cells produces a toxicity that impairs cell function leading to a diversity of phenotypes, from severe disease states to mild impacts on health. In fact, the ABCA1 variability is associated with myocardial infarction, cancer, type 2 diabetes, and metabolic syndrome \[[@B33]\]. Heterozygous states, nearly one-third of them, are associated with hypoalphalipoproteinemia, known as familial HDL deficiency syndrome (FHA). Two copies cause a more severe syndrome Tangier disease (TD) \[[@B34]--[@B38]\] described by reduced HDL-c plasma level (\<5%), impaired cholesterol efflux, and a trend to accumulate intracellular cholesterol \[[@B34]--[@B43]\]. Indeed, loss of function of ABCA1 mutations in TD patients has a major impact on lipoprotein metabolism. A failure to acquire apolipoproteins leads to a rapid catabolism of lipid-poor apoA1 and accumulation of lipids in macrophages, intestinal cells, platelet, and hepatocytes \[[@B34]--[@B38], [@B44]\]. Compared with unaffected family members, heterozygotes and homozygotes have a more prevalent, premature, and severe atherosclerosis \[[@B42]\].

Because high levels of HDL-c are atheroprotective there is considerable interest in developing agents that act to increase ABCA1 expression and thereby raise plasma HDL-c levels. The nsSNPs are important indicators of action sites and effective potential therapeutic approaches. Therefore, it is crucial to identify deleterious nsSNPs to characterize the genetic basis of diseases, assess individual susceptibility to these diseases, determinate molecular and therapeutic targets, and predict clinical phenotypes. Beyond the genetic level, a disease depends on the sequence and the structural location of the nsSNPs of the protein. While the nsSNPs occur all through the ABCA1 gene, they tend to cluster in the extracellular loops, the NBD, and the COOH-terminal region ([Figure 1](#fig1){ref-type="fig"}). In fact, three structural motifs have been functionally associated with disease: the ARA motif, an interface between NBD and TMD that forms a partially buried *α*-helix able to interact with the transmembrane helices, the conserved-loop 1, a allosteric loop between the membrane and globular domains, and the conserved-loop 2, an interaction surface for intracellular partners, critical in ATP-binding.

Even though many of nsSNP (rare or common) found in human ABCA1 have been identified, mainly in the HapMap project (<http://hapmap.ncbi.nlm.nih.gov/>), the molecular bases relating these variants and the caused phenotypes have not been studied in detail. To explore the effect of the large number of nsSNPs ABCA1 by experimental approaches would be extremely time-consuming and with low statistical chance. Alternatively, bioinformatic approaches, based on the biophysical severity of the amino acid exchange and the protein sequence and structural information, can offer a more feasible phenotype prediction. As such, MutPred (mutation prediction) \[[@B45]\] and PolyPhen2 (polymorphism phenotyping 2) algorithms \[[@B46]\], were used in this study to investigate the impact of all known nsSNPs on ABCA1 protein function. Besides, based on the results of*in vitro, in vivo*, and human studies of this gene in the literature we validated the predictions made by reviewing the effect of the most critical nsSNPs in ABCA1 gene and its pathological consequences.

2. Methods {#sec2}
==========

[Figure 2](#fig2){ref-type="fig"} shows the workflow designed to predict the nsSNPs effect on ABCA1 protein. ABCA1 human gene variants including SNPs, short insertions, and deletions were retrieved from Ensemble Variation 72 database 3141. Mutations were annotated using the SnpEff v3.2 toolbox \[[@B47]\] based on the human genome assembly GRCh37.68. Only variants found on the canonical transcript were considered for functional effect prediction, for what we used two different algorithms. PolyPhen2 (<http://genetics.bwh.harvard.edu/pph2/>) algorithm uses a naive Bayesian classifier to predict allele function based on a combination of sequence and structure-based attributes (if available) \[[@B46]\]. It calculates the probability for a given mutation to be benign, possibly damaging, or probably damaging. Then, we used MutPred (<http://mutpred.mutdb.org/>) \[[@B45]\] based upon SIFT algorithm \[[@B48]\] and a gain/loss of 14 predicted structural and functional properties. The predicted mutation outcome is based on a random forest (RF) classifier. The MutPred output includes the top 5 property scores and a general score (RF) equal to the probability of amino acid exchange is either deleterious or disease-associated. The ROC curves for both methods were generated using R programming language and the ROCR package ([Figure 3](#fig3){ref-type="fig"}) by a variation dataset obtained from VariBench (<http://structure.bmc.lu.se/VariBench/>) that contains mutations affecting protein tolerance including a neutral set of mutations comprising 17393 human coding nsSNPs and a pathogenic set of 14610 missense mutations obtained by manual curation from the PhenCode database.

Prediction accuracy accomplished by MutPred and PolyPhen2 depends on their specific criterion. Twelve structural and six sequence-based properties were used in this study ([Table 1](#tab1){ref-type="table"}). About 28% of validated nsSNPs in the Human Genome Variation Database are predicted to affect protein function \[[@B49]\]. Similarly, about 25% of nsSNPs affecting protein activity was predicted by PolyPhen2 \[[@B49]\]. MutPred offers classification accuracy with respect to human disease mutations. Considering conservative thresholds on the predicted disruption of molecular function, MutPred generates accurate and reliable hypotheses on the molecular basis of disease for about 11% of known inherited disease-causing mutations \[[@B45]\].

Our MutPred and PolyPhen2 predictions were validated by comparing them with previously obtained results from*in vitro, in vivo*, and human studies of ABCA1 gene in the databases and literature. When a given nsSNP found experimentally to be associated with a remarkable change of phenotype such as altered transporting activity or a disease was predicted by in silico methods as deleterious, it was considered that the prediction on this nsSNPs was correct. The prediction was defined as an error if such a deleterious nsSNP was predicted as tolerant.

3. Results and Discussion {#sec3}
=========================

The importance of ABCA1 in cholesterol efflux was demonstrated by the identification of ABCA1 mutations in TD and FHA families \[[@B34]--[@B38]\]. This has produced extensive research into the possibility to provide protection from atherosclerosis by increasing ABCA1 expression and thereby to raise plasma HDL-c levels. The identification of the large number of alleles for this transporter gene as target directly involved in HDL-c regulation constitutes a significant therapeutic strategy in reducing the risk for atherosclerosis.

3.1. Accuracy of the Prediction of the Functional Impact of nsSNPs {#sec3.1}
------------------------------------------------------------------

Out of a total of 3141 SNPs in ABCA1 gene retrieved from dbSNP, we found 233 nsSNPs, 126 sSNPs, 59 mRNA 3′-UTR SNPs, 12 mRNA 5′-UTR SNPs, and 2543 intronic SNPs ([Figure 4](#fig4){ref-type="fig"}). Among the 233 nsSNPs, MutPred (RF score \> 0.5) predicted 122 (52.36%) as deleterious whereas PolyPhen2 (pph2_prob \> 0.5) identified 97 (41.63%) as potentially damaging and damaging. Then, once that MutPred was used to predict the nsSNP disease-association probability, the damaging probability of nsSNPs was validated by PolyPhen2. A total of 80 (34.33%) nsSNPs were found to be deleterious by both methods. Among these 80 deleterious nsSNPs, the 29 (12.44%) targeted (MAF/NA) that resulted with high pathological phenotype (probability \> 0.8) are C1477R, W590L, W590S, A1046D, N1611D, M1091T, F2009S, N935H, R2081W, R1068H, N935S, R1068C, D1099Y, D1099N, W1699C, W840R, A937V, I1517R, C1660R, R1680W, P1065S, R1615P, T929I, Y2206D, L1379F, T940M, G1216V, Y2178H, and R1680Q. As shown in [Table 2](#tab2){ref-type="table"}, a good correlation index was obtained between the scores observed from the evolutionary-based approach MutPred and the structural-based approach PolyPhen2. As shown in [Figure 5](#fig5){ref-type="fig"}, the overall correlation of the predictions made by both methods is high (\~0.57). The majority of mutations classified as pathogenic by PolyPhen2 with the highest score (=1) are also classified as pathogenic by MutPred but within a score range between 0.51 and 1. The prediction accuracy depends not only by limitations of the in silico algorithms such as false positive error and interference of redundant motifs but also by the phenotype data from experimental studies \[[@B3]\].

Equally important is to consider the incorrect predictions in order to know the limitations of both algorithms and to suggest how they might be improved. Where MutPred predicts P2150L variant as deleterious, PolyPhen2 indicates a benign amino acid exchange. Conversely, MutPred predicted P85L to be probably damaging, while PolyPhen2 indicates it as neutral. Conflicting results were observed for a few other nsSNPs included in [Table 2](#tab2){ref-type="table"}. A total of seventeen deleterious nsSNPs predicted by PolyPhen2 resulted neutral by MutPred. In contrast, forty two deleterious nsSNPs by MutPred result neutral by PolyPhen2. We have observed ([Figure 5](#fig5){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}) that some mutational characteristics of nsSNPs such as C1477F, R666Q, P1475S, G616V, Q2210H, V1806M, and V304M show high PolyPhen2 values but very low MutPred scores due, at least in part, to loss or gain of catalytic residues and disorder and gain of ubiquitination and phosphorylation to the protein. On the other hand, some mutational characteristics of nsSNPs included T459P, A2028V, T774P, Q1279K, N1185K, D917N, E1005K, C887F, D1289N, Q188K, D462G, M1012I, R965C, S1181F, A255T, D457E, R496W, R1341T, R1925Q, R230C, L184S, R999L, and K1974R with low PolyPhen2 values but high MutPred scores produce, however loss of solvent accessibility and of disorder, gain of phosphorylation, and both loss and gain of molecular recognition features (MoRFs) binding, loss and gain of methylation, and loss and gain of helix structure. Both, loss and gain of catalytic residues are actively involved in human inherited disease. Also, the small ubiquitin---a 76 residue *β*-grasp protein---is about 95% conserved from yeast to human. Overall, both gain and loss of a phosphorylation site in a target protein may be important features for predicting cancer-causing mutations and may represent a molecular cause of disease for a number of inherited and somatic mutations. Changes in secondary structure impair large functional alterations, as well as the solvent accessibility degree. Therefore, inaccurate predictions occurred at these sites could be explicated not only for the limited effects of genetic variant but also for gene-environment interactions. Since the MutPred is based on a predicted structure of the protein under study rather than a solved structure as PolyPhen2 and considering the fact that nowadays the ABCA1 protein structure is only partially solved, it makes sense to prioritize the MutPred predictions. This fact was confirmed after evaluating the performance of both methods using a curated nsSNPs dataset with known outcome as a benchmark as shown in [Figure 3](#fig3){ref-type="fig"}. We have also observed that mostly, nsSNPs with verified functional effect in experimental studies are correctly predicted as damage variants by MutPred and PolyPhen2 tools. Still, controversial experimental data are obtained for those nsSNPs predicted as neutral by both of these methods.

3.2. Functional Assessment of ABCA1 Variants {#sec3.2}
--------------------------------------------

Disease-causing variants are under strong selective constraints, which determines if mutation frequency will increase, decrease, or change randomly during evolution. Most alterations are deleterious and so are finally removed during purifying selection. Benign mutations can sweep through the population and become fixed contributing to species differentiation. The ABCA1 gene is highly conserved between species. Human ABCA1 is 95.2% identical to mouse, 85.3% to chicken, 25.5% to drosophila, 21.6% to*C. elegans*, and 10.2% identical to fugu. In humans, there is an abundance of common nsSNPs that disrupt sites highly conserved across species and likely to be deleterious \[[@B50]\]. The information of nsSNPs can be used to outline the migration patterns of ancient humans and the ancestry of modern humans. Causal nsSNPs in single gene disorders are sufficient to impart large effects. Instead, complex traits are due to a much more complicated system of causative mechanisms that in aggregate increase the probability of disease. Genome-wide association studies reveal common genetic variants effects (common disease/common variant hypothesis) in complex traits. However, where common nsSNPs account for a relatively slight heritability of the traits, rare variants might produce large effects on the phenotype (rare variant/common disease hypothesis). The frequency range includes alleles that are exceptionally rare and even unique to an individual genome to be extremely common. Most deleterious nsSNPs are retained at low-population frequencies due to negative selection. Thus, variants with large effect tend to be rare and those that exert weak effects are more common. It is worthy to note that rare alleles can also have weak effect or no effect. A specific locus may contain numerous rare alleles, so there may be many rare variants with large effect and a few common variants with weak effects. Although it has not yet been possible to determine whether other variables are associated with specific nsSNPs frequencies, variants within metabolic genes are not randomly distributed along the human population but follow diverse ethnic and/or geographic-specific patterns. It has been reported \[[@B60]\] that a significant proportion (\~16%) of individuals with low HDL-c from the general population has the rare sequence of 25 variants in ABCA1 gene ([Table 2](#tab2){ref-type="table"}, MAF ≤ 0.01). However, consistent with MutPred and PolyPhen2 only nine of them, N1800H, W590L, S1731C, C1477R, D1706N, R1615P, R638Q, T2073A, and A1670T, are predicted as functionally impaired. Some deleterious mutations from some other genes have reached intermediate to high frequencies. Specifically, the ancestral APOE4 allele, remains higher in populations like Pygmies (0.41), Khoi San (0.37), Papuans (0.37), some Native Americans (0.28), Lapps (0.31) and aborigines of Malaysia (0.24), and Australia (0.26) \[[@B51]\]. The exposure of APOE4 to the current environmental conditions could have rendered it a susceptibility allele for cardiovascular and Alzheimer diseases. However, the prediction for variant within ABCA1 gene indicates lack of harmful alleles to MAF ≥ 0.01. Therefore we have evaluated and contrasted the predictions made for nsSNPs (rare/common) most widely studied for their role in cholesterol pathway by reviewing the effect of the most significant nsSNPs in ABCA1 gene and its pathological consequences.

### 3.2.1. Accurate Prediction of the Functionally Deleterious nsSNPs in the ABCA1 Gene {#sec3.2.1}

The**N1800H** ABCA1 has been fully characterized showing a complete lack of protein function in terms of cholesterol efflux and HDL production \[[@B52], [@B53]\]. Unlike the WT (wild-type), which is found at the endoplasmic reticulum and plasma membrane, N1800H is accumulated intracellularly \[[@B53]\]. Even similar physicochemical properties (polar, medium size) of exchanged residues the N1800H nsSNP, located between transmembrane domains \[[@B53]\], is a critical site for protein function. Scores from in silico methods predict the N1800H variant as highly deleterious.

The**W590L** was never studied, but the**W590S** ABCA1 variant affecting the same position is extensively known \[[@B53]\]. Distribution of W590S is identical to WT \[[@B54]\] as well as apoA1 binding activity \[[@B53]--[@B56]\]; however it shows defective lipid transport \[[@B53], [@B55], [@B57], [@B58]\]. Since multiple alignments often show a leucine residue in this position, it could be assumed that W590L had a similar behavior or even a lower impact than W590S on the protein function. Both W590S and W590L were predicted as deleterious nsSNPs with loss of functionality.

Studies indicate that**S1731C** variant alters the activity of ABCA1 protein \[[@B27], [@B60], [@B59]\]. This allele is present in French-Canadian families with low HDL-c levels \[[@B27]\] but not in subjects with normal \[[@B59]\] or high \[[@B60]\] HDL-c levels. Compared with WT, heterozygous show decreased \~60% the cholesterol efflux activity \[[@B27], [@B60], [@B61]\]. Interestingly, some but not all families harboring S1731C also carried the 2144X stop mutation \[[@B59]\] able to produce the most severe effects on HDL-c levels and on cholesterol efflux \[[@B62]\]. These data along with our in silico predictions indicate that conserved S1731C is highly likely to affect protein function.

**S1506L**,**Q597R**, and**C1477R** variants are linked to TD and FHA and found in tumor cancer \[[@B53]\]. Normal function of ABCA1 inhibits tumor growth in human cancer cells \[[@B53]\]. However, although expressed to similar levels as WT, these alleles show deficient cellular cholesterol efflux and HDL production and do not decrease tumor growth \[[@B17]\]. The three are located intracellularly but C1477R is also found in membrane \[[@B53]\], which indicates that membrane localization is essential but not sufficient for apoA1 binding \[[@B53], [@B63]\]. In fact, ApoA1 binds to ABCA1 protein oligomers but not with monomers \[[@B64]\]. Thus, conformation changes in binding sites might be produced by these nsSNPs found as deleterious by our in silico analysis.

The**R587W** reaches the cell surface but reduces the apoA1 binding efficiency \~50% \[[@B55]\]. Others studies indicate that this allele is mainly retained intracellularly decreasing cholesterol efflux and apoA1 binding \~75% \[[@B53]\]. Severe HDL deficiency \[[@B34]\] and premature CVD is caused by R587W \[[@B65]\]. This variant is highly conserved during evolution, and the in silico analysis predicts it as strongly damaging and disease-associated. Besides to be related with TD, the R587W as well as W590S variants are linked to AD. As the WT, these mutants significantly reduce A*β*-peptide synthesis \~45% \[[@B66]\], but increase by \~2-fold (R587W) and by 25% (W590S) amyloid precursor protein intracellular domain, a major cytotoxic of AD \[[@B66]\].

The**A1046D**, localized between conserved motifs \[[@B53], [@B67]\], shows an intermediate phenotype caused by its limited presence in the plasma membrane. This variant shows reduced apoA1 binding efficacy, poor HDL-c, and folding protein alteration. Both in silico methods predict A1046D as a functional residue with a probability to be deleterious very close to 1.

According to literature,**N1611D** is associated to probable atherosclerosis \[[@B62], [@B68]\]. The mutated protein expression was comparable to WT although cholesterol efflux from the cells was markedly reduced. Our theoretical results indicate very high probabilities of this nsSNP being deleterious, which indicate an adverse and potential harmful effect on ABCA1 function.

The**M1091T** variant exerts a dominant-negative impact on ABCA1 function with severe phenotype observed in subjects carrying this variant \[[@B42], [@B53], [@B62]\]. It is retained intracellularly preventing the protein from reaching the membrane \[[@B53]\]. In heterozygous, M1091T is lowered by 50% HDL and inhibits apoA1 binding and cholesterol efflux \[[@B53]\]. From evolutionary path, the inherited residue at this position has been methionine. Among related homologues ABCA2 and ABCA4 share a methionine at this position, while ABCA7 substitutes a leucine. Consistent with this fact, ABCA1 and ABCA7 are functionally divergent, with ABCA7 easing the efflux of phospholipids but not cholesterol \[[@B69]\]. Despite the modest conservation at this position, located in a critical cluster at the C-terminal region, in silico data suggest a severe-negative impact.

The**F2009S** is conserved between human and mouse, that along with the exchange from large size and aromatic (F) to small size and polar (S) explicates its reduced cholesterol efflux, low HDL-c, and apoA1 levels \[[@B70]\]. The functional effect produced by F2009S variant is consistent with our prediction made by PolyPhen2 and MutPred indicating a deleterious mutant.

The**N935S** variant is found intracellularly \[[@B53]\] in subjects without risk of premature atherosclerosis but with extremely low levels of HDL and signs of severe dementia and amyloid depositions in the brain \[[@B71], [@B72]\]. This variant was predicted as deleterious by the used methods.

**R1068H** mutation is located within the first ATP-binding domain. It is identified in TD homozygous \[[@B73]\]. Since the R1068H mutation is likely to produce a dysfunctional protein, one would expect it to be associated with FHA in the heterozygous state \[[@B73]\]. Residue R1068 is located in an *α*-helix of the Walker B motif in the NBD, vulnerable to interaction with D1092 and E1093 \[[@B74]\]. Homology modeling of the ABCA1 protein showed that the R1068H mutation disrupts the conformation of NBD. Functional studies of R1068H showed a lack of cholesterol efflux activity due to defective transference to the plasma membrane, mainly caused by impaired oligomerization \[[@B74]\]. The in silico analysis predicts a high possibility for R1068H to be damaging. Besides, a different mutation of this position,**R1068C**, predicted as a deleterious by our methods, has been reported in a compound heterozygote with almost no HDL \[[@B31]\].

**D1099Y** is located at possible interaction site and exchanges the medium size and acidic residue to the large and aromatic tyrosine. Surface residues not at defined interfaces are usually preserved. Still, a moderate to highly conserved domain on the surface of the structure includes this nsSNP, which is associated to familial HDL deficiency \[[@B70], [@B75]\] and predicted as deleterious in our analysis.

The**W1699C**, located within the transmembrane domain, is accumulated within the cytoplasm and a small proportion reaches the plasma membrane \[[@B76]\]. It introduces a cysteine residue, which stimulates the formation of a new disulphide bridge able to disrupt the ABCA1 protein structure preventing its oligomerization and transference to the plasma membrane. Probably, W1699C retains some residual functions, as shown by the plasma HDL-c levels found in members carrying this mutation which were not as low as might be expected in carriers \[[@B76]\]. In silico analysis with PolyPhen2 and MutPred indicate a deleterious effect of this nsSNP on ABCA1 function.

### 3.2.2. Controversial Results for Prediction of the Neutral nsSNPs in the ABCA1 Gene {#sec3.2.2}

The mutant**R1897W** that induces a change from basic (R) to aromatic (W) is predicted functionally neutral in this analysis. This variant was identified in the mother and the brother of an FHA patient, who had plasma HDL levels in the lower range of the normal values \[[@B77]\].

Both the**D1289N** and**P2150L** variants identified in TD patients are considered as disease causative \[[@B42], [@B78], [@B79]\]. Further experimental evidences disagreeing with these results suggest that both could be nonfunctional variants \[[@B60], [@B53], [@B80]\]. Indeed, they showed a lipid transport activity, apoA1 binding, and distribution similar to WT \[[@B53], [@B80]\]. Interestingly, P2150L is only found in patients who also harbor a second variant, the deleterious**R587W** described above \[[@B53]\]. Besides, TD patients with D1289N variant were homozygous for a second mutation R2081W that could cause the shown pathological phenotype \[[@B79]\].**R2081W** is missed at the plasma membrane and instead accumulated intracellularly \[[@B53]\]. Our results suggest that mutations R2081W and R587W are highly deleterious. For D1289N and P2150L variants, PolyPhen2 predicts a neutral impact on protein function contrary to MutPred predictions that indicates a high probability for these mutants to be deleterious. The positions 1289 and 2150 are conserved among all ABCA1 orthologs but with the close-related ABCA7 and ABCA4. Since conservation patterns in ABCA1 protein endure for a relatively short time in evolutionary path, it is hard to determine if the conservation at these positions is due to functional constraint or simply reflects random chance. Along with experimental data, this suggests that R2081W is a major responsible of ABCA1 protein dysfunction found in TD patients.

The rare**R219K** polymorphism is located on an N-terminal extracellular loop, which mediates ABCA1 protein interaction with apoA1 \[[@B39], [@B55], [@B57], [@B58]\]. Despite high number of case-control studies conducted to investigate the functionality of R219K variant the results have been inconclusive \[[@B59], [@B81]--[@B83]\]. While some reports suggest an association of R219K is with risk of CVD \[[@B84]\], other research indicates a decreased atherosclerosis progression in general population \[[@B59], [@B85]\]. Conversely, large prospective studies found no association with HDL-c levels or atherosclerosis susceptibility \[[@B82], [@B86]\]. A meta-analysis indicates that R219K polymorphism is protective against CVD in Asians but not in Caucasians \[[@B87]\]. Unexpectedly, the K219 allele was associated with a decreased risk of myocardial infarction \[[@B18], [@B59], [@B84]\]. Also, this variant has effect on triglycerides \[[@B59]\] but not with HDL-c \[[@B84]\] or with apoA1 levels \[[@B85]\]. Otherwise, a study indicates that blood lipid levels do not seem to be R219K dependent \[[@B88]\]. Whether this variant confers major susceptibility to CVD is for clarification. The association of R219K variant to risk of AD has been studied in diverse ethnic groups \[[@B18]--[@B20], [@B89], [@B90]\]. Although conflicting results were noted, a study observed a protective dependence in delaying the risk of late-onset AD \[[@B18]\]. Equal to other cases, experimental results inconclusive and contradictories result prediction of the R219K polymorphism was predicted to be neutral in our in silico analysis.

Some studies \[[@B59], [@B91]--[@B93]\] but not all \[[@B39], [@B94]\] indicate that**I883M** variant severely increases the risk of atherosclerosis and AD \[[@B20]\]. The I883M has been reported as a milder phenotype with a significant reduction of HDL-c and cholesterol efflux (\~70% of WT) \[[@B60]\]. In contrast, others studies \[[@B28], [@B59], [@B82], [@B83], [@B88]\] did not find any difference in lipid levels in I883M carriers. Studies among different healthy people \[[@B95], [@B96]\] as well as population with T2D \[[@B97]\] correlated the I883M variant with higher HDL-c concentration. Also, a stepwise regression approach identified I883M as one the key predictors of ischemic heart disease, whereas additive effects were found for V771M/I883M and I883M/E1172D pairs \[[@B82], [@B98]\]. As well, several studies have reported associations between V825I/I883M and increased plasma HDL-c levels \[[@B39], [@B67], [@B99]\]. Despite the controversial experimental results on the influence on cholesterol efflux activity observed of this polymorphism, our data predict that the I883M variant is functionally neutral. Interestingly, both alleles are found in the human population and the minor allele, methionine, is likely to be the ancestral allele at this position. Along with the human ABCA1orthologs, murine aligns valine at this position and the chimpanzee sequence aligns methionine. This divergence could explain why a simple conservation-based approach predicts the I883M change as neutral.

The**R1851Q** variant exchanges the large size and basic arginine (R) residue to medium size and polar glutamine predicted deleterious by MutPred and neutral by PolyPhen2. R1851Q occurs within the extracellular loop proximal to the transmembrane \[[@B68], [@B100]\]. Heterozygotes states show low HDL-c and apoA1 levels compared with those related to WT protein.

The**R230C** variant, found in Native American groups but not in European, Asian, or African individuals, has been associated with low levels of HDL-c and apoA1 \[[@B101]\]. These results are confirmed after adjusting for gender, BMI, and waist circumference \[[@B102]\]. Besides, the C230 allele is associated with obesity, metabolic syndrome, and T2D in Mexican population \[[@B101]\]. Still, R230C may have conferred resistance against certain infectious diseases \[[@B101]\]. R230C has been reported as a rare variant causing FHA in an Oji-Cree individual \[[@B67]\]. MutPred predicts a high probability of functional impairment of R230C, while that the PolyPhen2 program predicts the variant as neutral. Other facts that suggest functionally damage are (1) R230C occurs at the first extracellular loop, where TD and FHA mutations are clustered; (2) the arginine at position 230 is conserved between species; and (3) very different nature of residues involved; whereas arginine is basic and hydrophilic, the hydrophobic cysteine is vulnerable to disulfide bond.

The variants,**R1901S** that induces a change from large size and basic (R) to small size and polar (S);**Q2196H** that exchanges residues with similar physicochemical property (medium size, polar); and**E284K** that exchanges a medium size and acidic (E) to large size and basic (K), are predicted to be deleterious by MutPred and neutral by PolyPhen2. The R1901S and Q2196H variants occur within the C-terminal domain, close to the NBD, and E284K was located in the first extracellular loop, all of them associated to FHA \[[@B76]\]. The**A594T**,**I659V**,**T1512M**, and**R2004K** polymorphisms display different degrees of mislocalization to the plasma membrane and slight impacts on cholesterol efflux \[[@B103]\]. These nsSNPs were identified in low-HDL subjects \[[@B29]\]. The A594T, I659V, and T1512M were predicted to be functionally neutral and the R2004K mutation possibly damaging \[[@B29]\]. Finally, the novel mutation (**P85L**) in ABCA1 was identified in one family with low HDL but was not detected in over 400 chromosomes of healthy subjects \[[@B104]\]. Our in silico prediction indicated this variant as possible damaging by MutPred and neutral by PolyPhen2.

4. Conclusion and Future Directions {#sec4}
===================================

The practice of medicine, including health promotion and disease prevention, is primarily based on phenotype-based approaches. Most of them are proximal phenotypes achieved through biochemical markers. Finding genetic determinants of the phenotypes could not only clarify biological and functional consequence of variants but also might translate and extend to clinical phenotype. This focus would consider the large locus heterogeneity and numerous nongenetic factors to contribute to the phenotype. Since high levels of HDL-c are atheroprotective, there is extensive interest in developing agents that enhance ABCA1 expression and thereby raise plasma HDL-c levels. Amino acid exchange variants are crucial indicators of action sites and effective potential therapeutic approaches. In fact, nsSNPs represent disease modifiers capable of altering drug/nutrient response and potential targets vulnerable to environmental factors.

Evaluation of 233 nsSNPs (rare or common) found in ABCA1 transporter indicates that the rare 29 (12.44%) of them resulted to be highly deleterious with a probability \>0.8. From 20 sequence variants found in about 16% of individuals with low HDL cholesterol only nine of them, D1706N, R1615P, W590L, C1477R, N1800H, R638Q, T2073A, A1670T, and S1731C, were predicted by MutPred and PolyPhen2 as functionally impaired. We have observed that mostly nsSNPs with verified functional effect in all experimental studies made are correctly predicted as damage variants by MutPred and PolyPhen2 tools. However, controversial experimental data are obtained for those nsSNPs predicted as neutral by both methods. Presumably clinical phenotype is the result of the additive effects and interactions among multiple alleles with different effect degree. Multiple rare alleles in ABCA1 contribute to plasma HDL-c levels in the general population.

Predicting the phenotypic consequence of nsSNPs using computational algorithms provides a better understanding of genetic differences in susceptibility to diseases and drug/nutrient response. These methods predict whether an amino acid altering mutation is deleterious or disease-causing based on physicochemical properties, population frequency, protein structure, and cross-species conservation. However, computational prediction tools are generally based on machine learning algorithms, which need to be trained before classifying a mutation as either neutral or deleterious. A major obstacle of these approaches is the lack of experimentally validated and impartial data sets. A further complication is that mutations in highly conserved sequences do not always produce phenotypes that are easily noticeable. Besides, knowledge of protein structure is crucial to accurately predict functional nsSNPs and understand their linkage with disease. Severe limitation arises thus when protein 3D-structure is not available as the ABCA1 case. Thus, an accurate, efficient, and generally applicable approach is needed to establish a genotype/phenotype correlation. Whole genome sequencing is likely to become a commodity that could be readily available at a reasonable cost and be easily accommodated into the decision making tree of health care of every individual. The challenging task will be to identify variants that are disease-causing or likely disease-causing and develop strategies to prevent and attenuate the evolving phenotype. Likewise, various complementary studies, genetic and biological, would be necessary to discern the associated alleles from the true disease-causing variants. Moreover a better understanding of genome components, such as functional, large intergenic noncoding RNAs, small noncoding RNAs, and primary transcripts, would be essential. An integrated approach that utilizes genomics, transcriptomic, proteomics, and metabolomic would be expected to facilitate identification and characterization of the mechanisms involved in the pathogenesis of the phenotype.
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![Predicted structure of ABCA1 \[[@B21], [@B23], [@B105]\]. The protein consists of 2261 amino acids and comprises 2 halves of similar structure. Each half encodes a transmembrane domain containing 6 helices (1--6 and 7--12) and 1 nucleotide binding domain (NBD-1 and NBD-2), where ATP is bound and utilized as energy for substrate transport across the membrane. Each NBD contains 2 highly conserved peptide motifs known as Walker A and Walker B, which are present in many proteins that use ATP and a Walker C signature unique to ABC transporters. ABCA1 is predicted to have an N terminus oriented into the cytosol and two large extracellular loops that are highly glycosylated and linked by cysteine bonds (Y indicates the glycosylation sites, and S--S indicates predicted disulfide bonds).](CHOLESTEROL2014-639751.001){#fig1}

![Workflow for predicting the effect of nsSNPs on ABCA1 protein. Gene specific variations were retrieved from the main variation databases. Mutations were annotated and nsSNPs belonging to the canonical transcript were selected in order to run the algorithms for functional prediction.](CHOLESTEROL2014-639751.002){#fig2}

![ROC (receiver operating characteristics) curve comparing the performance of MutPred and PolyPhen2 methods in predicting the outcome of nsSNPs. The dashed curve corresponds to MutPred predictions. As the area under the curve (AUC) for the MutPred method predictions is larger than the areas over the curve (AOC) which corresponds to the PolyPhen2 predictions curve, we can confirm that MutPred outperforms PolyPhen2 in predicting the outcome of nsSNPs. The dataset used for the performance comparison was obtained from Varibench as stated in Methods section.](CHOLESTEROL2014-639751.003){#fig3}

![Distribution of ABCA1 nonsynonymous SNPs (nsSNPs), synonymous SNPs (sSNPs), 3′-UTR and 5′-UTR, and intronic SNPs.](CHOLESTEROL2014-639751.004){#fig4}

![Scatter plot shows the correlation between the predictions made by PolyPhen2 (*x*-axis) and MutPred (*y*-axis) for 233 amino acid substitutions on ABCA1. The diagonal line represents a perfect correlation (=1) between both prediction methods for every mutation. The overall correlation of the predictions made by both methods is high (0.57). The majority of mutations classified as pathogenic by PolyPhen2 with the highest score (=1) are also classified as pathogenic by MutPred but within a score range between 0.51 and 1.](CHOLESTEROL2014-639751.005){#fig5}

###### 

Structural and functional properties used by MutPred and PolyPhen2.

                                                  PolyPhen2   MutPred
  ----------------------------------------------- ----------- ---------
  Sequence based properties                                    
   Bond annotation                                X            
   Functional site annotation                     X           X
   Region annotation                              X           X
   PHAT score                                     X            
   PSIC score                                     X            
   SIFT score                                                 X
   Evolutionary attributes                        X           X
  Structural properties                                        
   Secondary structure                            X           X
   Solvent-accessible surface area                X           X
   Phi-psi dihedral angles                        X            
   Normalized accessible surface area             X            
   Change in accessible surface propensity        X            
   Change in residue side chain volume            X            
   Region of the phi-psi map (Ramachandran map)   X            
   Normalized B-factor                            X           X
   Ligand contacts                                X            
   Interchain contacts                            X            
   Functional site contacts                       X            
   Molecular Recognition Fragments (MoRFs)                    X

###### 

Functional effects of nsSNPs for ABCA1 gene (UniProt: O95477) predicted by PolyPhen2 and MutPred. A score \>0.5 means that the mutation is classified as damaging by the algorithms. In addition, MutPred algorithm formulates hypotheses about structural and functional impact of the mutation; the most statistically significant hypothesis is reported in this table. The MAP column includes Minor Allele Frequency. The deviation column represents how close the two predicted scores are; a value of 0 corresponding to identical values.

  Mutation   pph2_prob   Polyphen class   RFscore   Mutpred hypothesis                       MAF          Deviation
  ---------- ----------- ---------------- --------- ---------------------------------------- ------------ ------------
  A1010V     0,104       neutral          0,816     Loss of ubiquitination at K1009          NA           0,50346003
  A1046D     0,999       deleterious      0,938     Loss of MoRF binding                     NA           0,04313351
  A1182T     0,001       neutral          0,425     Loss of sheet                            0,00045914   0,29981328
  A1407T     0,119       neutral          0,277     Gain of helix                            0,00045914   0,11172287
  A1631V     0,401       neutral          0,321     Loss of sheet                            NA           0,05656854
  A1670T     0,997       deleterious      0,566     Gain of glycosylation at A1670           NA           0,30476302
  A1756T     0,81        deleterious      0,418     Gain of glycosylation at A1756           NA           0,27718586
  A2028V     0,146       neutral          0,564     Gain of methylation at K2023             0            0,29557064
  A255T      0           neutral          0,755     Loss of helix                            NA           0,53386562
  A343V      0,001       neutral          0,227     Loss of disorder                         NA           0,15980613
  A391S      0,318       neutral          0,34      Gain of disorder                         NA           0,01555635
  A594T      0,02        neutral          0,406     Loss of catalytic residue at A594        NA           0,27294322
  A697T      0,416       neutral          0,508     Gain of sheet                            0,00045914   0,06505382
  A746G      1           deleterious      0,608     Loss of stability                        0,00045914   0,27718586
  A779T      0,411       neutral          0,468     Loss of helix                            NA           0,04030509
  A795S      0,07        neutral          0,494     Loss of helix                            NA           0,29981328
  A937V      0,991       deleterious      0,921     Loss of disorder                         NA           0,04949748
  C1477F     1           deleterious      0,496     Loss of catalytic residue at C1477       NA           0,35638182
  C1477R     1           deleterious      0,852     Gain of methylation at C1477             NA           0,10465181
  C1660R     0,954       deleterious      0,917     Gain of methylation at C1660             NA           0,02616295
  C3S        0,005       neutral          0,48      Gain of disorder                         NA           0,33587572
  C887F      0,002       neutral          0,604     Gain of phosphorylation at S884          0,00137741   0,42567828
  D1018G     0,992       deleterious      0,535     Loss of catalytic residue at D1018       NA           0,3231478
  D1099N     1           deleterious      0,906     Gain of sheet                            NA           0,06646804
  D1099Y     1           deleterious      0,946     Loss of disorder                         NA           0,03818377
  D1263E     0,003       neutral          0,214     Gain of helix                            NA           0,14919953
  D1289N     0,339       neutral          0,573     Gain of sheet                            NA           0,16546299
  D1553E     0,001       neutral          0,273     Loss of helix                            NA           0,19233304
  D1706N     1           deleterious      0,611     Loss of helix                            NA           0,27506454
  D2243E     0,078       neutral          0,491     Gain of relative solvent accessibility   0,00459137   0,2920351
  D434E      0,005       neutral          0,413     Gain of disorder                         NA           0,28849957
  D441N      0           neutral          0,348     Loss of helix                            NA           0,24607316
  D444E      0           neutral          0,338     Loss of helix                            NA           0,23900209
  D446E      0           neutral          0,301     Loss of helix                            NA           0,21283914
  D457E      0,001       neutral          0,566     Loss of helix                            NA           0,39951533
  D462G      0,071       neutral          0,555     Loss of catalytic residue at D462        NA           0,34223968
  D581E      0,38        neutral          0,346     Loss of helix                            NA           0,02404163
  D677E      0,158       neutral          0,846     Loss of loop                             NA           0,48648947
  D831N      0,999       deleterious      0,589     Gain of helix                            NA           0,28991378
  D917N      0,1         neutral          0,577     Gain of MoRF binding                     NA           0,33728994
  E1005K     0,026       neutral          0,542     Gain of MoRF binding                     NA           0,3648671
  E1172D     0,003       neutral          0,253     Loss of sheet                            0,0509642    0,1767767
  E1172G     0,003       neutral          0,281     Loss of sheet                            0,00091827   0,19657569
  E1253K     0,048       neutral          0,453     Gain of ubiquitination at E1253          NA           0,28637825
  E1916A     0,027       neutral          0,34      Gain of MoRF binding                     0,00183655   0,22132442
  E226G      0,019       neutral          0,47      Loss of stability                        NA           0,31890516
  E284K      0,206       neutral          0,842     Gain of methylation at E284              NA           0,44971991
  E815G      0,072       neutral          0,361     Loss of disorder                         NA           0,20435386
  E868K      0,051       neutral          0,69      Gain of methylation at E868              0,00275482   0,45184123
  F1285L     0,001       neutral          0,235     Loss of loop                             NA           0,16546299
  F1573S     0,065       neutral          0,532     Gain of disorder                         NA           0,33021887
  F2009S     0,811       deleterious      0,932     Gain of disorder                         NA           0,08555992
  F2082V     0,266       neutral          0,442     Gain of MoRF binding                     NA           0,12445079
  F2163S     0,939       deleterious      0,727     Loss of sheet                            NA           0,14990664
  F346L      0           neutral          0,239     Gain of disorder                         NA           0,16899852
  F426L      0,94        deleterious      0,549     Gain of helix                            0,00045914   0,27647875
  F632C      0,998       deleterious      0,694     Loss of stability                        0,00045914   0,21496046
  F950S      0,995       deleterious      0,664     Gain of disorder                         NA           0,23405235
  G1049R     1           deleterious      0,638     Gain of MoRF binding                     NA           0,25597266
  G1216V     0,951       deleterious      0,844     Loss of ubiquitination at K1214          NA           0,07566043
  G1321A     0,936       deleterious      0,715     Gain of catalytic residue at G1321       NA           0,15627061
  G156V      0,017       neutral          0,389     Loss of helix                            NA           0,26304372
  G2147E     0,49        neutral          0,397     Loss of catalytic residue at S2148       NA           0,06576093
  G315W      0,997       deleterious      0,526     Loss of disorder                         NA           0,33304729
  G616V      0,998       deleterious      0,444     Loss of disorder                         NA           0,39173716
  G788W      1           deleterious      0,664     Loss of catalytic residue at P784        NA           0,23758788
  G851R      0,998       deleterious      0,71      Gain of catalytic residue at G851        NA           0,20364675
  H263D      0           neutral          0,399     Loss of helix                            NA           0,28213561
  H551D      0,613       deleterious      0,468     Gain of sheet                            NA           0,10253048
  I1084V     0,241       neutral          0,511     Gain of MoRF binding                     NA           0,19091883
  I1239V     0,078       neutral          0,376     Loss of catalytic residue at L1244       NA           0,21071782
  I1517R     0,962       deleterious      0,917     Gain of catalytic residue at I1517       NA           0,03181981
  I1555T     0,439       neutral          0,484     Loss of stability                        NA           0,03181981
  I1911T     0,006       neutral          0,437     Loss of stability                        0,00045914   0,30476302
  I35V       0,066       neutral          0,31      Loss of helix                            0,00045914   0,17253406
  I546V      0           neutral          0,31      Gain of MoRF binding                     NA           0,2192031
  I560T      0,829       deleterious      0,496     Loss of stability                        NA           0,23546656
  I649F      0,97        deleterious      0,669     Loss of catalytic residue at I649        NA           0,21283914
  I659V      0,034       neutral          0,405     Loss of methylation at K663              NA           0,26233662
  I883M      0,002       neutral          0,296     Gain of disorder                         0,365473     0,20788939
  K1250R     0,118       neutral          0,377     Loss of methylation at K1250             0,00045914   0,18314066
  K1587R     0,034       neutral          0,377     Gain of helix                            0,410927     0,24253763
  K166R      0           neutral          0,251     Loss of ubiquitination at K166           NA           0,1774838
  K1761T     0,038       neutral          0,545     Loss of methylation at K1761             0,00045914   0,35850314
  K1974R     0,158       neutral          0,679     Loss of ubiquitination at K1974          NA           0,36840263
  K2040E     0,243       neutral          0,459     Loss of MoRF binding                     0,00045914   0,15273507
  K401Q      0,007       neutral          0,322     Loss of ubiquitination at K401           NA           0,22273864
  K613E      0,002       neutral          0,428     Loss of ubiquitination at K613           0,00045914   0,30122749
  K776N      0,985       deleterious      0,568     Loss of methylation at K776              0,00183655   0,29486353
  L1041V     0,999       deleterious      0,625     Loss of ubiquitination at K1040          0,00137741   0,26445794
  L1379F     0,987       deleterious      0,866     Loss of catalytic residue at L1379       NA           0,08555992
  L1408F     0,443       neutral          0,418     Loss of stability                        0,00045914   0,01767767
  L1648P     0,961       deleterious      0,749     Loss of stability                        NA           0,14990664
  L184S      0,007       neutral          0,576     Loss of sheet                            0,00045914   0,40234376
  L184W      0,928       deleterious      0,54      Gain of helix                            0,00045914   0,27435743
  L2032M     0,897       deleterious      0,688     Gain of methylation at K2036             NA           0,14778532
  L2168P     0,984       deleterious      0,693     Gain of disorder                         NA           0,20576807
  L2187Q     0,995       deleterious      0,698     Gain of disorder                         0,00045914   0,21001071
  M1012I     0,008       neutral          0,595     Loss of catalytic residue at V1008       NA           0,41507168
  M1091T     0,98        deleterious      0,955     Gain of disorder                         NA           0,01767767
  M233V      0           neutral          0,417     Loss of stability                        NA           0,29486353
  M415L      0,002       neutral          0,423     Gain of relative solvent accessibility   NA           0,29769196
  M674L      0,534       deleterious      0,599     Loss of catalytic residue at M674        0,00045914   0,04596194
  N1185K     0,01        neutral          0,583     Gain of MoRF binding                     NA           0,40517219
  N1185S     0,002       neutral          0,358     Gain of helix                            NA           0,25173001
  N1406K     0,006       neutral          0,408     Gain of ubiquitination at N1406          NA           0,28425693
  N1611D     0,968       deleterious      0,921     Loss of MoRF binding                     NA           0,03323402
  N1800H     0,758       deleterious      0,826     Loss of stability                        NA           0,04808326
  N1800S     0,241       neutral          0,84      Loss of stability                        NA           0,42355696
  N2119Y     0,96        deleterious      0,727     Loss of MoRF binding                     NA           0,16475588
  N820S      0,001       neutral          0,348     Loss of catalytic residue at N820        NA           0,24536605
  N935H      0,996       deleterious      0,966     Gain of disorder                         NA           0,02121321
  N935S      0,831       deleterious      0,969     Gain of disorder                         NA           0,09758074
  P1065S     0,998       deleterious      0,906     Gain of MoRF binding                     NA           0,06505382
  P1475S     1           deleterious      0,235     Gain of phosphorylation at P1475         NA           0,54093669
  P1878T     0,019       neutral          0,482     Gain of helix                            NA           0,32739044
  P2150L     0,068       neutral          0,826     Loss of disorder                         NA           0,53598694
  P248A      0           neutral          0,207     Loss of helix                            NA           0,1463711
  P250L      0           neutral          0,244     Loss of glycosylation at P250            NA           0,17253406
  P641L      1           deleterious      0,603     Gain of MoRF binding                     NA           0,28072139
  P855S      0,97        deleterious      0,59      Loss of catalytic residue at W856        NA           0,26870058
  P85L       0,394       neutral          0,618     Loss of disorder                         0,00045914   0,15839192
  Q1279K     0,032       neutral          0,715     Gain of MoRF binding                     NA           0,48295393
  Q188K      0,001       neutral          0,543     Gain of ubiquitination at Q188           0            0,38325188
  Q205E      0,01        neutral          0,255     Loss of loop                             NA           0,17324116
  Q205R      0           neutral          0,279     Gain of helix                            NA           0,19728279
  Q2196H     0,011       neutral          0,798     Loss of MoRF binding                     NA           0,55649304
  Q2210H     0,984       deleterious      0,388     Gain of catalytic residue at D2214       NA           0,42143564
  Q597R      1           deleterious      0,71      Gain of MoRF binding                     NA           0,20506097
  Q849R      0,689       deleterious      0,662     Gain of methylation at Q849              NA           0,01909188
  R104C      0,985       deleterious      0,589     Loss of MoRF binding                     NA           0,28001429
  R1068C     1           deleterious      0,962     Loss of MoRF binding                     NA           0,02687006
  R1068H     1           deleterious      0,972     Loss of MoRF binding                     NA           0,01979899
  R1082C     1           deleterious      0,694     Loss of MoRF binding                     NA           0,21637468
  R1195Q     0,044       neutral          0,364     Loss of loop                             NA           0,22627417
  R1195W     0,952       deleterious      0,589     Gain of catalytic residue at A1194       NA           0,25667976
  R126H      0           neutral          0,467     Loss of MoRF binding                     NA           0,33021887
  R1273L     0,007       neutral          0,35      Loss of loop                             NA           0,24253763
  R1283C     0,001       neutral          0,449     Gain of ubiquitination at K1278          NA           0,31678384
  R1341T     0,016       neutral          0,604     Loss of methylation at R1341             ≤0,001       0,41577879
  R1344W     0,993       deleterious      0,64      Loss of methylation at K1345             0,00045914   0,24960869
  R1417H     0,837       deleterious      0,457     Loss of phosphorylation at T1416         0,00183655   0,26870058
  R1615P     0,947       deleterious      0,895     Loss of methylation at R1615             ≤0,001       0,03676955
  R1615Q     0,187       neutral          0,679     Gain of helix                            NA           0,34789654
  R1680Q     0,997       deleterious      0,807     Gain of ubiquitination at K1683          NA           0,13435029
  R1680W     1           deleterious      0,911     Loss of disorder                         NA           0,06293251
  R1839H     0,006       neutral          0,48      Loss of phosphorylation at S1842         0,00045914   0,33516861
  R1851Q     0,015       neutral          0,897     Gain of catalytic residue at R1851       NA           0,62366818
  R1897W     0,009       neutral          0,408     Probably damaging                        NA           0,28213561
  R1901S     0,091       neutral          0,81      Gain of phosphorylation at R1901         NA           0,50840978
  R1925Q     0,006       neutral          0,69      Loss of MoRF binding                     0,00229568   0,48366104
  R2004K     0,911       deleterious      0,699     Gain of ubiquitination at R2004          NA           0,14990664
  R2030Q     0,032       neutral          0,442     Loss of MoRF binding                     NA           0,28991378
  R2081W     0,998       deleterious      0,936     Loss of MoRF binding                     NA           0,04384062
  R2173Q     0,008       neutral          0,382     Gain of sheet                            NA           0,26445794
  R2189G     0,142       neutral          0,443     Loss of MoRF binding                     NA           0,21283914
  R219K      0           neutral          0,41      Gain of ubiquitination at R219           0,419192     0,28991378
  R230C      0           neutral          0,68      Loss of MoRF binding                     0,00734619   0,48083261
  R306G      0,04        neutral          0,463     Loss of helix                            ≤0,001       0,29910617
  R306H      0,899       deleterious      0,431     Loss of helix                            NA           0,33092597
  R369H      0,937       deleterious      0,433     Loss of MoRF binding                     NA           0,35638182
  R437Q      0,088       neutral          0,48      Loss of helix                            NA           0,27718586
  R437W      0,991       deleterious      0,562     Gain of catalytic residue at L435        NA           0,30334881
  R443K      0           neutral          0,44      Loss of stability                        0,00045914   0,31112698
  R496W      0,209       neutral          0,576     Loss of loop                             NA           0,25950819
  R500H      0,013       neutral          0,519     Loss of helix                            NA           0,35779603
  R587W      1           deleterious      0,688     Loss of disorder                         NA           0,22061732
  R638Q      0,957       deleterious      0,664     Loss of methylation at R638              NA           0,20718229
  R638W      0,999       deleterious      0,671     Loss of methylation at R638              0,00045914   0,23193102
  R666Q      1           deleterious      0,437     Gain of ubiquitination at K668           NA           0,39810112
  R666W      1           deleterious      0,56      Gain of catalytic residue at R666        NA           0,31112698
  R672Q      0,832       deleterious      0,501     Loss of MoRF binding                     NA           0,23405235
  R965C      0,302       neutral          0,608     Loss of disorder                         ≤0,001       0,21637468
  R999C      0,127       neutral          0,766     Loss of solvent accessibility            NA           0,45184123
  R999L      0,208       neutral          0,748     Loss of solvent accessibility            NA           0,38183766
  S107A      0,002       neutral          0,342     Gain of helix                            NA           0,24041631
  S1141Y     0,805       deleterious      0,306     Loss of phosphorylation at S1141         NA           0,35284628
  S1157N     0,022       neutral          0,355     Gain of sheet                            0,00045914   0,23546656
  S116N      0,196       neutral          0,241     Loss of phosphorylation at S116          NA           0,03181981
  S1181F     0,042       neutral          0,542     Loss of disorder                         0,00045914   0,35355339
  S1255R     0,027       neutral          0,326     Loss of glicosilation at S1255           0,00183655   0,21142493
  S1280R     0,009       neutral          0,351     Gain of sheet                            0,00045914   0,24183052
  S1376G     0,007       neutral          0,407     Gain of methylation at K1373             ≤0,001       0,28284271
  S139G      0           neutral          0,284     Gain of helix                            NA           0,20081833
  S1506L     0,996       deleterious      0,733     Loss of helix                            NA           0,18596908
  S1536F     0,998       deleterious      0,594     Loss of disorder                         NA           0,28567114
  S1731C     0,893       deleterious      0,526     Loss of helix                            ≤0,001       0,25950819
  S212T      0,028       neutral          0,375     Gain of helix                            0,00459137   0,24536605
  S2182F     0,578       deleterious      0,498     Loss of disorder                         NA           0,05656854
  S2186F     0,862       deleterious      0,458     Loss of disorder                         NA           0,28567114
  S442R      0,001       neutral          0,449     Loss of helix                            NA           0,31678384
  S713G      1           deleterious      0,576     Loss of stability                        NA           0,29981328
  S780N      0,996       deleterious      0,559     Loss of stability                        NA           0,30900566
  T1175M     0,432       neutral          0,331     Loss of sheet                            0,00091827   0,07141779
  T1242M     0,993       deleterious      0,62      Loss of catalytic residue at T1242       NA           0,26375083
  T1399M     0,003       neutral          0,279     Loss of glycosylation at T1399           NA           0,19516147
  T1401I     0,003       neutral          0,368     Loss of glycosylation at T1401           NA           0,25809398
  T1427M     0,005       neutral          0,352     Gain of catalytic residue at T1427       0,00091827   0,24536605
  T2073A     0,852       deleterious      0,657     Loss of phosphorylation at T2073         ≤0,001       0,13788582
  T459P      0,03        neutral          0,534     Gain of helix                            ≤0,001       0,35638182
  T515A      0,04        neutral          0,449     Gain of helix                            NA           0,28920667
  T774P      0,003       neutral          0,61      Gain of methylation at K776              0,00183655   0,42921382
  T929I      0,946       deleterious      0,889     Loss of disorder                         NA           0,04030509
  T940M      1           deleterious      0,844     Loss of methylation at K939              NA           0,11030866
  V1054I     0,951       deleterious      0,51      Loss of ubiquitination at K1052          NA           0,31183409
  V1096I     0           neutral          0,467     Gain of helix                            NA           0,33021887
  V1158I     0,065       neutral          0,226     Loss of sheet                            NA           0,11384419
  V1674I     0,053       neutral          0,376     Loss of catalytic residue at V1674       0,00137741   0,22839549
  V1704D     0,752       deleterious      0,876     Loss of helix                            NA           0,08768124
  V1806M     0,98        deleterious      0,417     Gain of ubiquitination at K1804          NA           0,39810112
  V1858M     0,305       neutral          0,472     Loss of catalytic residue at V1858       NA           0,11808683
  V2035M     0,042       neutral          0,38      Loss of methylation at K2036             NA           0,23900209
  V2244I     0,002       neutral          0,386     Gain of sheet                            NA           0,271529
  V304M      0,823       deleterious      0,387     Gain of disorder                         NA           0,30829856
  V380I      0,001       neutral          0,353     Gain of methylation at K376              NA           0,24890159
  V399A      0,071       neutral          0,563     Gain of disorder                         0,00183655   0,34789654
  V408G      0,101       neutral          0,431     Loss of stability                        NA           0,23334524
  V481L      0,001       neutral          0,374     Gain of sheet                            0,00045914   0,26375083
  V589I      0,004       neutral          0,334     Gain of catalytic residue at V589        0,00091827   0,23334524
  V654G      0,433       neutral          0,438     Loss of stability                        NA           0,00353553
  V702A      0,002       neutral          0,408     Loss of stability                        NA           0,28708535
  V724M      0,833       deleterious      0,462     Loss of catalytic residue at V724        0,00045914   0,26233662
  V771M      0,034       neutral          0,421     Loss of ubiquitination at K776           0,0606061    0,27365032
  V825I      0,001       neutral          0,401     Loss of catalytic residue at V825        0,128099     0,28284271
  W1699C     1           deleterious      0,915     Gain of catalytic residue at L1700       NA           0,06010408
  W590L      0,841       deleterious      0,888     Loss of helix                            ≤0,001       0,03323402
  W590S      0,889       deleterious      0,857     Gain of disorder                         ≤0,001       0,02262742
  W840R      0,998       deleterious      0,923     Gain of methylation at W840              NA           0,05303301
  Y1921H     0,986       deleterious      0,752     Gain of disorder                         NA           0,16546299
  Y2178H     0,982       deleterious      0,826     Gain of disorder                         NA           0,11030866
  Y2206D     0,992       deleterious      0,878     Gain of sheet                            NA           0,08061017
  Y482C      0,03        neutral          0,826     Gain of loop                             NA           0,56285691
  Y835H      0,967       deleterious      0,653     Loss of stability                        NA           0,22203153
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